Chromium Hba1c Randomized Trial Evidence Table

Structured evidence table for Chromium Hba1c Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Chromium Hba1c Randomized Trial1 1 2 Table 1 Aspect Details References Metabolic syndrome is a cluster of conditions that increase the risk of heart disease, stroke, and diabetes.1Babakr Abdullatif Taha (2026)Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes
Chromium Hba1c Randomized Trial1 [] Common risk factors include obesity (BMI ≥ 25 kg/m), increased waist circumference (>102 cm for men, >88 cm for women), hypertension, smoking, hyperlipidemia, age > 40 years, and a history of gestational diabetes.1Babakr Abdullatif Taha (2026)Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes
Chromium Hba1c Randomized Trial5 [] Metabolic syndrome increases the risk of cardiovascular diseases, kidney disease, eye problems, neuropathy, and diabetes-related complications such as foot ulcers and amputations.1Babakr Abdullatif Taha (2026)Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes
Chromium Hba1c Randomized TrialIt includes central obesity, insulin resistance, hypertension, and dyslipidemia.1Babakr Abdullatif Taha (2026)Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes
Chromium Hba1c Randomized TrialWhile chronic hyperglycemia remains the principal driver of DR, growing evidence suggests that dysregulation of essential trace elements, including magnesium, zinc, manganese, chromium, selenium, and iron, may contribute to retinal microvascular injury through oxidative stress and impaired endothelial function.1Gopal N (2025)Role of Trace Elements in Diabetic Retinopathy: A Systematic Review.
Chromium Hba1c Randomized TrialSelenium exhibited a U-shaped relationship, with both low and high levels associated with increased DR risk.1Gopal N (2025)Role of Trace Elements in Diabetic Retinopathy: A Systematic Review.
Chromium Hba1c Randomized TrialDysregulation of iron, particularly deficiency and evidence of iron-driven ferroptosis, was linked to retinal hypoxia, neurodegeneration, and elevated oxidative stress.1Gopal N (2025)Role of Trace Elements in Diabetic Retinopathy: A Systematic Review.
Chromium Hba1c Randomized TrialDiabetic retinopathy (DR) is a leading cause of vision impairment worldwide and a major microvascular complication of type 2 diabetes mellitus (T2DM).1Gopal N (2025)Role of Trace Elements in Diabetic Retinopathy: A Systematic Review.
topicChromium Hba1c Randomized Trial
claim1 1 2 Table 1 Aspect Details References Metabolic syndrome is a cluster of conditions that increase the risk of heart disease, stroke, and diabetes.
evidence level1
citationBabakr Abdullatif Taha (2026)
sourceChromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes
topicChromium Hba1c Randomized Trial
claim1 [] Common risk factors include obesity (BMI ≥ 25 kg/m), increased waist circumference (>102 cm for men, >88 cm for women), hypertension, smoking, hyperlipidemia, age > 40 years, and a history of gestational diabetes.
evidence level1
citationBabakr Abdullatif Taha (2026)
sourceChromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes
topicChromium Hba1c Randomized Trial
claim5 [] Metabolic syndrome increases the risk of cardiovascular diseases, kidney disease, eye problems, neuropathy, and diabetes-related complications such as foot ulcers and amputations.
evidence level1
citationBabakr Abdullatif Taha (2026)
sourceChromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes
topicChromium Hba1c Randomized Trial
claimIt includes central obesity, insulin resistance, hypertension, and dyslipidemia.
evidence level1
citationBabakr Abdullatif Taha (2026)
sourceChromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes
topicChromium Hba1c Randomized Trial
claimWhile chronic hyperglycemia remains the principal driver of DR, growing evidence suggests that dysregulation of essential trace elements, including magnesium, zinc, manganese, chromium, selenium, and iron, may contribute to retinal microvascular injury through oxidative stress and impaired endothelial function.
evidence level1
citationGopal N (2025)
sourceRole of Trace Elements in Diabetic Retinopathy: A Systematic Review.
topicChromium Hba1c Randomized Trial
claimSelenium exhibited a U-shaped relationship, with both low and high levels associated with increased DR risk.
evidence level1
citationGopal N (2025)
sourceRole of Trace Elements in Diabetic Retinopathy: A Systematic Review.
topicChromium Hba1c Randomized Trial
claimDysregulation of iron, particularly deficiency and evidence of iron-driven ferroptosis, was linked to retinal hypoxia, neurodegeneration, and elevated oxidative stress.
evidence level1
citationGopal N (2025)
sourceRole of Trace Elements in Diabetic Retinopathy: A Systematic Review.
topicChromium Hba1c Randomized Trial
claimDiabetic retinopathy (DR) is a leading cause of vision impairment worldwide and a major microvascular complication of type 2 diabetes mellitus (T2DM).
evidence level1
citationGopal N (2025)
sourceRole of Trace Elements in Diabetic Retinopathy: A Systematic Review.

Source documents

  1. Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes
  2. Role of Trace Elements in Diabetic Retinopathy: A Systematic Review.